Torin 1

Catalog No.S2827

Molecular Weight(MW): 607.62

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

5 Customer Reviews

Huh-7.5 cells were treated with increasing concentration of Torin 1, a known autophagy inducer, and the autophagy response was assessed by measuring LC3II and p62 levels.

Am J Pathol 2014 184(1), 214-29. Torin 1 purchased from Selleck.

Flag-tagged SENP3 was immunoprecipitated from HeLa cells and used for in vitro phosphorylation assay with [32P]ATP with either the mock-treated or Torin1-treated mTOR/Raptor/MLST8 complex. (Upper) The samples then were subjected to SDS-PAGE, followed by autoradiography. mTOR autophosphorylation is indicated by an asterisk. (Lower) Immunopurified SENP3 was monitored by Western blotting with anti-Flag antibody.

Mol Cell Biol 2014 34(24), 4474-84. Torin 1 purchased from Selleck.
Exp Cell Res, 2018, 363(1):84-94. Torin 1 purchased from Selleck.

Representative Western blots showing LC3 in PP242 (PP) or Torin1 (Tor) treated HepG2 cells. HepG2 cells were treated with 10 uM PP242 or 0.1 uM Torin1 for 24 h.

Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.05.047. Torin 1 purchased from Selleck.
Bone marrow derived macrophages were pre-treated with 10nM Torin 1 for 1h prior to LPS treatment (100 ng/ml). TNF-a production was analyzed 24h later.

Lim Hsiu Kim, Lina from National University of Singapore. Torin 1 purchased from Selleck.

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

Targets

mTORC1 ^[1] (Cell-free assay)	mTOR ^[2] (Cell-free assay)	DNA-PK ^[2] (Cell-free assay)	mTORC2 ^[1] (Cell-free assay)	p110γ ^[2] (Cell-free assay)	View More
2 nM	4.32 nM	6.34 nM	10 nM	171 nM	View More

In vitro

Torin1 inhibits phosphorylation of mTORC1 and mTORC2 substrates in cells at concentrations of 2 and 10 nM, respectively. Moreover, Torin1 exhibits 1000-fold selectivity for mTOR over PI3K (EC50 = 1800 nM) and exhibits 100-fold binding selectivity relative to 450 other protein kinases. ^[1] ^[2] Torin1 causes cell cycle arrest through a rapamycin-resistant mechanism that is also independent of mTORC2. Torin1 disrupts mTORC1-dependent phenotypes more completely than rapamycin. Rapamycin-resistant functions of mTORC1 are required for cap-dependent translation. ^[1] In a recent study, it is reported Torin1 increases neurotensin secretion and gene expression through activation of the MEK/ERK/c-Jun pathway in the human endocrine cell line BON. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
ETK-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2Lw[WlEPTB;MD6wNFA{ODZizszN	M2PPR3NCVkeHUh?=
OCUB-M	NV7TPXhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M13IcmlEPTB;MD6wNFE6PCEQvF2=	NVXKPZVbW0GQR1XS
DOHH-2	MnmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEj6XVJKSzVyPUCuNFAzOjVizszN	NVvkfIZUW0GQR1XS
NOS-1	M4\2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;3U4I2UUN3ME2wMlAxOjR{IN88US=>	NUjHbVlTW0GQR1XS
L-363	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2D1emlEPTB;MD6wNFI5PCEQvF2=	MXzTRW5ITVJ?
RL95-2	MlH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPGTWM2OD1yLkCwN\|Ih\|ryP	NGnROoFUSU6JRWK=
BL-70	NYjqNnhOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M135WGlEPTB;MD6wNFM{PyEQvF2=	MojxV2FPT0WU
TGBC1TKB	NIjPemhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zne2lEPTB;MD6wNFM4QSEQvF2=	M2LYUnNCVkeHUh?=
697	MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXRfYZKSzVyPUCuNFA3OzRizszN	M3Lrc3NCVkeHUh?=
RPMI-8226	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;TVGNbUUN3ME2wMlAxPjVzIN88US=>	MnnlV2FPT0WU
BL-41	NUfE[VYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTBwMEC2PVYh\|ryP	MVPTRW5ITVJ?
MRK-nu-1	M2PVfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTBwMEC3NFch\|ryP	MojvV2FPT0WU
EW-1	NWiz[mo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUna[\|dXUUN3ME2wMlAxPzR7IN88US=>	NYnMOW9tW0GQR1XS
EVSA-T	Mn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXmxU5o1UUN3ME2wMlAxQDl{IN88US=>	M{XlWnNCVkeHUh?=
HUTU-80	M2HvN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml:4TWM2OD1yLkCwPVI6KM7:TR?=	NH:y[2tUSU6JRWK=
VA-ES-BJ	MmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlyyTWM2OD1yLkCwPVg1KM7:TR?=	MWrTRW5ITVJ?
GCIY	NILRdnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITMZ5JKSzVyPUCuNFExODdizszN	MUjTRW5ITVJ?
ES6	NXHvZ3VzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTBwMEGwPFMh\|ryP	MWPTRW5ITVJ?
NALM-6	MkTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2P6dGlEPTB;MD6wNVExOiEQvF2=	NVfVWnpGW0GQR1XS
LB996-RCC	M1;OPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTkSplKSzVyPUCuNFEyOzdizszN	MlSxV2FPT0WU
EW-16	NWnvb5FIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\FXGlEPTB;MD6wNVE6OiEQvF2=	MVLTRW5ITVJ?
KALS-1	M{nnbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3Pnb2lEPTB;MD6wNVE6QCEQvF2=	NFrqNHBUSU6JRWK=
OPM-2	NEnzOoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnWTWM2OD1yLkCxNlkh\|ryP	NGS4R3JUSU6JRWK=
KU812	NWfFRYkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXZdY5lUUN3ME2wMlAyOjl4IN88US=>	M1OwfXNCVkeHUh?=
A4-Fuk	M3vZNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LQR2lEPTB;MD6wNVMyQSEQvF2=	NH:2NlVUSU6JRWK=
KGN	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXVOYk{UUN3ME2wMlAyOzV7IN88US=>	NXLZc2VmW0GQR1XS
KS-1	MlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTBwMEGzPVIh\|ryP	NH3GZ4FUSU6JRWK=
no-11	NEPmR3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LCRmlEPTB;MD6wNVM6PSEQvF2=	NGfBVIFUSU6JRWK=
PSN1	M{fqTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXkTWM2OD1yLkCxOFA6KM7:TR?=	M2j2R3NCVkeHUh?=
SK-LMS-1	NXLrbXdPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDJTJdKSzVyPUCuNFE1OTNizszN	NIjEN\|lUSU6JRWK=
LS-411N	NHyyV\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLzfXE2UUN3ME2wMlAyPDN7IN88US=>	NHWwO41USU6JRWK=
HT-144	MmDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTBwMEG0OVEh\|ryP	NYe1R2VxW0GQR1XS
ACN	NGjBR5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfKT5lPUUN3ME2wMlAyPSEQvF2=	MXfTRW5ITVJ?
RKO	NIGwWWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXPdI9KSzVyPUCuNFE2OzNizszN	M1PNXnNCVkeHUh?=
CMK	M1TTU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTuTWM2OD1yLkCxOVQ{KM7:TR?=	NGexOIZUSU6JRWK=
GB-1	NEHRbVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{D4[GlEPTB;MD6wNVU2OyEQvF2=	MoTSV2FPT0WU
KE-37	NHHZXlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnf5TWM2OD1yLkCxOVc{KM7:TR?=	NEDjRWRUSU6JRWK=
no-10	NX65OXpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDsR5NKSzVyPUCuNFE2QDRizszN	MU\TRW5ITVJ?
MOLT-16	Ml[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{S1[GlEPTB;MD6wNVYzOiEQvF2=	NX3NcGZuW0GQR1XS
HEL	Mo\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nUNWlEPTB;MD6wNVY1KM7:TR?=	M2rYS3NCVkeHUh?=
NCI-H1355	MlTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjOZW97UUN3ME2wMlAyPjR4IN88US=>	MoH5V2FPT0WU
IST-MEL1	Mm\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7wUGRkUUN3ME2wMlAyPzd2IN88US=>	M17wTXNCVkeHUh?=
MHH-PREB-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXztfHlvUUN3ME2wMlAyQDF6IN88US=>	M4OyV3NCVkeHUh?=
ES8	NHL6TGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\EbHF1UUN3ME2wMlAyQDR2IN88US=>	M{jPUHNCVkeHUh?=
LC-2-ad	NEW5b3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXX4[WFtUUN3ME2wMlAzOTN5IN88US=>	M12z[nNCVkeHUh?=
LAMA-84	NVW2RVRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjRPHBKSzVyPUCuNFIyPjdizszN	NH;rb4NUSU6JRWK=
BV-173	NYHkbG1NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPGT3BKSzVyPUCuNFIzODNizszN	NX73TGFKW0GQR1XS
SW872	MkTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo[wTWM2OD1yLkCyNlQ4KM7:TR?=	MUDTRW5ITVJ?
SK-UT-1	MnTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\UZmlKSzVyPUCuNFIzPjFizszN	MkHkV2FPT0WU
OS-RC-2	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTBwMEKzNlMh\|ryP	M1LJUXNCVkeHUh?=
NCI-H747	M{fxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwMEKzN{DPxE1?	NXf2O4FsW0GQR1XS
MZ2-MEL	MkL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DUUWlEPTB;MD6wNlM{PyEQvF2=	MmjkV2FPT0WU
TE-11	MoH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1X3O2lEPTB;MD6wNlM4OiEQvF2=	M3HtPXNCVkeHUh?=
KURAMOCHI	M1:2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7VSJJqUUN3ME2wMlAzPDF2IN88US=>	NVfLe\|l[W0GQR1XS
HD-MY-Z	NEHhVG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjWVFQ4UUN3ME2wMlAzPDJ4IN88US=>	MmXOV2FPT0WU
GI-1	MnfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1W3U2lEPTB;MD6wNlQ3QSEQvF2=	NWnWZoRQW0GQR1XS
LB1047-RCC	NXnwNnhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVSyRYRtUUN3ME2wMlAzPDh6IN88US=>	MVTTRW5ITVJ?
TE-12	M3\DWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmG3TWM2OD1yLkCyOVUh\|ryP	MWHTRW5ITVJ?
MZ7-mel	M3LWT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvNTWM2OD1yLkCyOlA6KM7:TR?=	MoHvV2FPT0WU
MMAC-SF	M3PZ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1n5emlEPTB;MD6wNlY{OyEQvF2=	MnjPV2FPT0WU
A101D	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmP6TWM2OD1yLkCyOlUh\|ryP	MYTTRW5ITVJ?
GR-ST	NUDVRY9ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTBwMEK2OVUh\|ryP	NHvCT5hUSU6JRWK=
MC116	MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTBwMEK2PEDPxE1?	MU\TRW5ITVJ?
Ramos-2G6-4C10	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVG5TlIzUUN3ME2wMlAzPzVizszN	NEnxZ\|ZUSU6JRWK=
ATN-1	MnH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjZd4tKSzVyPUCuNFI4QDlizszN	NUjs[odXW0GQR1XS
MFH-ino	M1HxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVSzPJV2UUN3ME2wMlAzQDF{IN88US=>	M2Xj[nNCVkeHUh?=
DEL	NYK1XYYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXSOXNKSzVyPUCuNFI5OTVizszN	M3fMV3NCVkeHUh?=
OCI-AML2	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXvvNIRrUUN3ME2wMlAzQDdzIN88US=>	MXHTRW5ITVJ?
LXF-289	Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHwTWM2OD1yLkCyPFczKM7:TR?=	M3L4cHNCVkeHUh?=
IA-LM	NFnIOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoXpTWM2OD1yLkCyPVE4KM7:TR?=	NYjCPHBRW0GQR1XS
EoL-1-cell	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTBwMEK5PVYh\|ryP	MoTyV2FPT0WU
OVCAR-4	M1PLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHXXZo5UUN3ME2wMlA{ODl2IN88US=>	NFHoclJUSU6JRWK=
ES1	M2nBRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTBwMEOwPVch\|ryP	MoLtV2FPT0WU
CESS	NXL1O4g{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnwOGJKSzVyPUCuNFMxQTlizszN	NUfmV5BrW0GQR1XS
GAK	NI\tSm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnT1TWM2OD1yLkCzNVg3KM7:TR?=	Mlm3V2FPT0WU
NTERA-S-cl-D1	Mn[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETve4RKSzVyPUCuNFMzOjZizszN	NH\pem1USU6JRWK=
TE-10	NYHmTWpnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfC[pRvUUN3ME2wMlA{OzFzIN88US=>	M2LDWnNCVkeHUh?=
CCRF-CEM	NFrLfIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTBwMEOzO\|Eh\|ryP	MWfTRW5ITVJ?
NMC-G1	M2frPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvCS4dSUUN3ME2wMlA{PDR6IN88US=>	NH35[Y9USU6JRWK=
HOP-62	NFjqSmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\MVIhZUUN3ME2wMlA{PTV4IN88US=>	MmPKV2FPT0WU
SH-4	NUDDdFlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTBwMEO1PFIh\|ryP	NHu1SHRUSU6JRWK=
NCI-H1648	MlzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTBwMEO2NlIh\|ryP	NUDJ[lBbW0GQR1XS
EB-3	MnHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PtcGlEPTB;MD6wN\|Y1OyEQvF2=	MkPiV2FPT0WU
BB65-RCC	M3nnVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvPTWM2OD1yLkCzOlkyKM7:TR?=	MmTTV2FPT0WU
BE-13	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3j5S2lEPTB;MD6wN\|c2QSEQvF2=	MVvTRW5ITVJ?
CP67-MEL	MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTBwMEO3OVkh\|ryP	NYTrNoZLW0GQR1XS
SW954	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\GTWM2OD1yLkCzO\|kh\|ryP	MVPTRW5ITVJ?
TE-5	NV;HdmNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHKwbZVKSzVyPUCuNFM5PTRizszN	Ml7WV2FPT0WU
HCE-4	NYO1bmtYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7xWppKSzVyPUCuNFM5PTVizszN	MnnpV2FPT0WU
LC-1F	NWTidlY5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTEfW5IUUN3ME2wMlA{QTh7IN88US=>	NVTqVnRVW0GQR1XS
TK10	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPiTWM2OD1yLkC0NFE6KM7:TR?=	MVvTRW5ITVJ?
SJSA-1	NUSxNZFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDLd41KSzVyPUCuNFQyQDhizszN	MoLZV2FPT0WU
Daudi	MlnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTBwMESyNlUh\|ryP	Mle2V2FPT0WU
SW982	NIPsO4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4ThVGlEPTB;MD6wOFI1PiEQvF2=	MWrTRW5ITVJ?
SF126	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1TYdGlEPTB;MD6wOFM3OSEQvF2=	NY\GdY4{W0GQR1XS
TE-15	MkLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LhXmlEPTB;MD6wOFQ{PSEQvF2=	NFewNXFUSU6JRWK=
COLO-684	M{HvUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXP0NFV4UUN3ME2wMlA1PTZzIN88US=>	NIPoWmVUSU6JRWK=
8-MG-BA	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\oTWM2OD1yLkC0OlI6KM7:TR?=	M2CxTXNCVkeHUh?=
NB13	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml60TWM2OD1yLkC0O\|c3KM7:TR?=	M2X6R3NCVkeHUh?=
HCC1599	NFHpV5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\Xc\|QzUUN3ME2wMlA1QDd7IN88US=>	NIGzeJlUSU6JRWK=
SK-PN-DW	NIjIOFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTBwMES5OFkh\|ryP	M1TS[3NCVkeHUh?=
ALL-PO	NU[4b3FNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTBwMES5OVYh\|ryP	NIXaZ3NUSU6JRWK=
NB6	MnrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTQTWM2OD1yLkC1NlcyKM7:TR?=	M{nhcnNCVkeHUh?=
IST-SL2	M{CyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnPU4tWUUN3ME2wMlA2OzZ{IN88US=>	MWTTRW5ITVJ?
BB30-HNC	NGDsclZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTBwMEW3N{DPxE1?	NXvuUoRGW0GQR1XS
SW962	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\DT\|hKSzVyPUCuNFU4PjNizszN	MVrTRW5ITVJ?
TGBC24TKB	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fpW2lEPTB;MD6wOVc6QSEQvF2=	NFnRc\|FUSU6JRWK=
KINGS-1	MlTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTBwMEW4NFMh\|ryP	NHLQ[WpUSU6JRWK=
HC-1	NWj2UppLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTBwMEW4Nlch\|ryP	NVPTTYNCW0GQR1XS
RS4-11	NIPZNlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILSUoFKSzVyPUCuNFU6OzhizszN	NETETohUSU6JRWK=
LS-123	M2D6N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jzNGlEPTB;MD6wOVk1OiEQvF2=	M1HBO3NCVkeHUh?=
A3-KAW	NVnOWpZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFv6OJlKSzVyPUCuNFYzOjVizszN	MXvTRW5ITVJ?
SNB75	MkLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{TzR2lEPTB;MD6wOlM1OSEQvF2=	M4HkeHNCVkeHUh?=
SR	M3f3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4mwcGlEPTB;MD6wOlM4PCEQvF2=	MoPDV2FPT0WU
LOUCY	NXTXW3RGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTBwME[zPVQh\|ryP	NH7hW2dUSU6JRWK=
K5	M{DlTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmO4TWM2OD1yLkC2OFA{KM7:TR?=	M3rYVHNCVkeHUh?=
Becker	M{O3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{PDWmlEPTB;MD6wOlQzKM7:TR?=	NE\CeHlUSU6JRWK=
CTV-1	M{XwNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnG5TWM2OD1yLkC2OVQ5KM7:TR?=	M{nTV3NCVkeHUh?=
KLE	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\mcWlEPTB;MD6wOlU5PCEQvF2=	NXLTW3hnW0GQR1XS
MZ1-PC	MmjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPSTWM2OD1yLkC2OVk5KM7:TR?=	NX;NNodpW0GQR1XS
MOLT-4	M3\I[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\KTWM2OD1yLkC2OlA2KM7:TR?=	MUnTRW5ITVJ?
MLMA	M3r4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHmUGN7UUN3ME2wMlA3PzhizszN	M3q3NXNCVkeHUh?=
A388	NXH4XIdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\nblVKSzVyPUCuNFY5QTNizszN	MXnTRW5ITVJ?
MV-4-11	NGHkU2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\GR2FKSzVyPUCuNFY6QTVizszN	Mk\wV2FPT0WU
DSH1	M3P3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LFU2lEPTB;MD6wO\|E4OyEQvF2=	M3jMZ3NCVkeHUh?=
MONO-MAC-6	MoLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjFTWM2OD1yLkC3NlEzKM7:TR?=	MVXTRW5ITVJ?
ARH-77	M2LuZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\VcosyUUN3ME2wMlA4Ojd6IN88US=>	NYrFN\|ZoW0GQR1XS
LB771-HNC	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4n2WGlEPTB;MD6wO\|U1QSEQvF2=	MlXvV2FPT0WU
PF-382	NH3PcIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmP0TWM2OD1yLkC3OVY6KM7:TR?=	MULTRW5ITVJ?
KM12	M2[5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLHRmNzUUN3ME2wMlA4PjRizszN	M165Z3NCVkeHUh?=
HAL-01	NX;HXZdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjnNpBKSzVyPUCuNFc3PThizszN	MXXTRW5ITVJ?
RPMI-8402	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH20SpFKSzVyPUCuNFc4QDlizszN	NX3nOHlsW0GQR1XS
OMC-1	NUSyU2hWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTBwMEe4NFQh\|ryP	MmfEV2FPT0WU
HT	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTBwMEig{txO	NYrm[IloW0GQR1XS
QIMR-WIL	M1PVZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV31fGlkUUN3ME2wMlA5ODV3IN88US=>	MUHTRW5ITVJ?
KNS-42	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG[xfY5KSzVyPUCuNFgzODNizszN	MWLTRW5ITVJ?
BC-3	NXjHSoVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDuRpRXUUN3ME2wMlA5OjB2IN88US=>	M3;TNHNCVkeHUh?=
ES4	NULyeIptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTBwMEiyPVYh\|ryP	MlmyV2FPT0WU
NCI-H23	NFTRelVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPXTWM2OD1yLkC4OFQh\|ryP	NIG5Z5JUSU6JRWK=
LB2518-MEL	NEHZPWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrYbYJKSzVyPUCuNFg3QTZizszN	MU\TRW5ITVJ?
LC4-1	NGTRXmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFy5NYhKSzVyPUCuNFg4OzhizszN	NGnXbWdUSU6JRWK=
SIG-M5	NGTJWpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTBwMEi5NFQh\|ryP	NH7NUm1USU6JRWK=
LP-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFv0NVVKSzVyPUCuNFg6OzhizszN	MW\TRW5ITVJ?
TE-8	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLyTnU5UUN3ME2wMlA6ODF4IN88US=>	NIfYXFdUSU6JRWK=
K-562	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVixUmpNUUN3ME2wMlA6OTJizszN	MmTsV2FPT0WU
J-RT3-T3-5	MnPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7JcJRuUUN3ME2wMlA6OTV\|IN88US=>	NEDxPWFUSU6JRWK=
DU-4475	M4rWWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTBwMEmxOlUh\|ryP	MnzzV2FPT0WU
RXF393	MkHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTBwMEm0OlIh\|ryP	NIjteJlUSU6JRWK=
NB5	M1SxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTOeG45UUN3ME2wMlA6PjJ3IN88US=>	MmTEV2FPT0WU
A704	NX\DdGxJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTBwMEm3OFEh\|ryP	MlLkV2FPT0WU
SF268	M3TwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nuS2lEPTB;MD6wPVgzPSEQvF2=	NGnSUJlUSU6JRWK=
UACC-257	M3;hcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfJNYVKSzVyPUCuNFk5OzNizszN	NFrEfIlUSU6JRWK=
L-428	NGDQW3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\CR3FKSzVyPUCuNVA{OiEQvF2=	MlvwV2FPT0WU
ST486	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3e4d2lEPTB;MD6xNFYxPiEQvF2=	Mn\YV2FPT0WU
SK-MM-2	NVXhRXZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1j0T2lEPTB;MD6xNFcxQSEQvF2=	M4nw[HNCVkeHUh?=
COR-L279	NI\iU2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfPbFJjUUN3ME2wMlExQDN{IN88US=>	NXTEZ3lMW0GQR1XS
JiyoyeP-2003	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\hbJRKSzVyPUCuNVA5PDNizszN	M4DPV3NCVkeHUh?=
GT3TKB	NXHLSIM3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HqbmlEPTB;MD6xNFkyQCEQvF2=	NI\BUHpUSU6JRWK=
HCE-T	NFr2UplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XERmlEPTB;MD6xNFk1KM7:TR?=	M1jSS3NCVkeHUh?=
SBC-1	NX\hOFR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mli4TWM2OD1yLkGxNVE6KM7:TR?=	MVfTRW5ITVJ?
KNS-81-FD	NF75UWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUW3bmM4UUN3ME2wMlEyOjd\|IN88US=>	M3y0cHNCVkeHUh?=
NCI-H2126	NHXMUWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTBwMUGzPVQh\|ryP	MlLBV2FPT0WU
EM-2	NHTodJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PROGlEPTB;MD6xNVUzQSEQvF2=	MnK3V2FPT0WU
JAR	NHrnc4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF[0XXlKSzVyPUCuNVE2QThizszN	MWTTRW5ITVJ?
NB17	NUjMd\|NOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPHOlZGUUN3ME2wMlEyPjV{IN88US=>	MWrTRW5ITVJ?
LB647-SCLC	MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPjXVlbUUN3ME2wMlEyPzB3IN88US=>	Mn7SV2FPT0WU
CAL-148	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoniTWM2OD1yLkGxPEDPxE1?	NU\UUpk4W0GQR1XS
K052	NXntXJJrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVr1OYp3UUN3ME2wMlEyQDVzIN88US=>	M3[1fHNCVkeHUh?=
KARPAS-299	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1X3d2lEPTB;MD6xNlI{OyEQvF2=	NV;OZmt4W0GQR1XS
KARPAS-422	M2\Q[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPaSmRiUUN3ME2wMlEzPDN{IN88US=>	MWjTRW5ITVJ?
LOXIMVI	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTBwMUK1NVUh\|ryP	NFLpUJVUSU6JRWK=
SCC-3	Mk\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzyTWM2OD1yLkGyPFUyKM7:TR?=	MY\TRW5ITVJ?
LU-139	NIjuNZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTBwMUK5O\|Uh\|ryP	M3XjfXNCVkeHUh?=
COLO-320-HSR	NV3zeoRIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTBwMUOwPFYh\|ryP	Mo[zV2FPT0WU
ONS-76	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDHfXBKSzVyPUCuNVMyOyEQvF2=	M4fSenNCVkeHUh?=
U-266	NXLjVnBbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTBwMUOyOFUh\|ryP	MUDTRW5ITVJ?
HH	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vxNWlEPTB;MD6xN\|U{PSEQvF2=	MkHCV2FPT0WU
BB49-HNC	MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPOZVF2UUN3ME2wMlE{PTh5IN88US=>	M{L4S3NCVkeHUh?=
NCI-SNU-5	NXjCSpRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknFTWM2OD1yLkGzOVk3KM7:TR?=	NHToPHBUSU6JRWK=
C2BBe1	M3yxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;MZ2REUUN3ME2wMlE{PzR4IN88US=>	M3fVe3NCVkeHUh?=
ML-2	NYDYdmdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUi1SHZ3UUN3ME2wMlE{QTV\|IN88US=>	M{i4ZXNCVkeHUh?=
SCH	NGOwe41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnseWxxUUN3ME2wMlE{QTd2IN88US=>	MVvTRW5ITVJ?
NCI-H82	NGPuWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTwPHNOUUN3ME2wMlE1OTB2IN88US=>	M3njOXNCVkeHUh?=
MDA-MB-134-VI	NVnFSYZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLOTWM2OD1yLkG0NlUzKM7:TR?=	MlHaV2FPT0WU
SK-N-DZ	M1zlbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFX3VmFKSzVyPUCuNVQ4OTlizszN	Mlm0V2FPT0WU
HL-60	NE\LSXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTBwMUS5NkDPxE1?	M3LjVnNCVkeHUh?=
LB373-MEL-D	MnXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTBwMUW1N\|kh\|ryP	M1;6N3NCVkeHUh?=
LB831-BLC	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkO1TWM2OD1yLkG2NFc3KM7:TR?=	M3XvenNCVkeHUh?=
SK-NEP-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTBwMU[xNFEh\|ryP	NFz6eFJUSU6JRWK=
IMR-5	M3\LTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnwU2VUUUN3ME2wMlE3PDh\|IN88US=>	MVXTRW5ITVJ?
Calu-6	Mor0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrvcllxUUN3ME2wMlE3PTN5IN88US=>	NISyV2tUSU6JRWK=
NCI-H1882	M3T6fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTBwMU[3Nlgh\|ryP	MW\TRW5ITVJ?
NCI-H446	M4DHN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7WTWM2OD1yLkG2PFkyKM7:TR?=	NGLZeIdUSU6JRWK=
GI-ME-N	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGKzbINKSzVyPUCuNVgxOiEQvF2=	MUXTRW5ITVJ?
MPP-89	NVXDWVhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLJTWM2OD1yLkG4NVIyKM7:TR?=	MUnTRW5ITVJ?
CGTH-W-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\XTWM2OD1yLkG4OFM3KM7:TR?=	M1THcHNCVkeHUh?=
MEG-01	NIixb4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3jEdmlEPTB;MD6xPFYzQCEQvF2=	NFvXZ5FUSU6JRWK=
NCI-H748	M3\reGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTBwMUi5NVEh\|ryP	MXnTRW5ITVJ?
COLO-829	NXrHdJJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;oTWM2OD1yLkKwOlc{KM7:TR?=	MnzOV2FPT0WU
GOTO	Ml7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHYV3lKSzVyPUCuNlA4OyEQvF2=	MkGwV2FPT0WU
EW-3	NYPNSooyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTBwMkG3NVgh\|ryP	MljRV2FPT0WU
KY821	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDiNJp5UUN3ME2wMlIzODR3IN88US=>	MUPTRW5ITVJ?
CTB-1	M1THdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPQWGF1UUN3ME2wMlIzOjJ6IN88US=>	MWPTRW5ITVJ?
TALL-1	NELRUWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{j0fWlEPTB;MD6yNlkzOSEQvF2=	MYDTRW5ITVJ?
NCI-H209	M{PUVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\PfXFKSzVyPUCuNlI6PjJizszN	NUPNSnUzW0GQR1XS
IST-MES1	MmrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTBwMkO1NUDPxE1?	NXv3SnNkW0GQR1XS
DMS-114	MkXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XLNWlEPTB;MD6yN\|k6OyEQvF2=	Mlm1V2FPT0WU
SNU-C2B	MonPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVj3d\|FTUUN3ME2wMlI1OzF4IN88US=>	MYHTRW5ITVJ?
DG-75	MnvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILmPJdKSzVyPUCuNlYyQTVizszN	NIPYPXhUSU6JRWK=
D-336MG	M17VSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3rXcWlEPTB;MD6yOlU2PyEQvF2=	M1zB[HNCVkeHUh?=
KMOE-2	MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\sPWlEPTB;MD6yO\|U{QCEQvF2=	M1z1WXNCVkeHUh?=
NB1	NWH6U3lRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjITWM2OD1yLkK3PVI3KM7:TR?=	MnXuV2FPT0WU
RH-1	MkfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{m2PGlEPTB;MD6yO\|k5QSEQvF2=	NGL2UpVUSU6JRWK=
TE-1	NIPkT45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fEdGlEPTB;MD6yPFQ4QSEQvF2=	NXi4RZF6W0GQR1XS
RPMI-6666	NYLad\|lxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTBwMki4OEDPxE1?	NVHHWZZmW0GQR1XS
TE-9	NFT1XXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrqc3FKSzVyPUCuNlg6QDVizszN	MWTTRW5ITVJ?
BT-474	MnXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWm5Noh4UUN3ME2wMlI6OzN2IN88US=>	NVzhTHdiW0GQR1XS
COLO-668	M2LMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnqVpJzUUN3ME2wMlI6PDJ7IN88US=>	MU\TRW5ITVJ?
NCI-H1581	NIDwUlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFXnN2RKSzVyPUCuNlk3QDlizszN	NI[weXBUSU6JRWK=
MN-60	NFfh[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYG0VFBRUUN3ME2wMlI6QTB3IN88US=>	NVHW[HNFW0GQR1XS
L-540	NHe3NXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlflTWM2OD1yLkOwNFgyKM7:TR?=	NYPZS24zW0GQR1XS
MOLT-13	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\tfGlEPTB;MD6zNFE5OyEQvF2=	M175[XNCVkeHUh?=
NCI-SNU-16	M4H2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrrTWM2OD1yLkOwNlA2KM7:TR?=	M1PjNnNCVkeHUh?=
NCI-H64	MmPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTBwM{CzN\|Eh\|ryP	NHLKSVNUSU6JRWK=
CP66-MEL	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLORm9PUUN3ME2wMlMyPDF3IN88US=>	NXvQUoJ1W0GQR1XS
NB69	M{\lW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTBwM{KxPFgh\|ryP	MYPTRW5ITVJ?
NCI-H2196	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHL0[\|RKSzVyPUCuN\|MxOzZizszN	NYDVUHVEW0GQR1XS
MHH-CALL-2	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIr4UWpKSzVyPUCuN\|M1PjhizszN	NX;WPWZlW0GQR1XS
HCC2157	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXT0cFlQUUN3ME2wMlM{QTV2IN88US=>	M{nQ[3NCVkeHUh?=
LS-1034	M{\VO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVS0[IdPUUN3ME2wMlM3Ozh6IN88US=>	MVzTRW5ITVJ?
BOKU	NY\WPVN6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\TOWlEPTB;MD6zO\|E6QSEQvF2=	M4fpcHNCVkeHUh?=
GDM-1	Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fzSmlEPTB;MD6zO\|I{PCEQvF2=	MnHJV2FPT0WU
TGW	M4D1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH:wWIZKSzVyPUCuN\|c1PTNizszN	MX;TRW5ITVJ?
SNU-C1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTBwM{iyNVUh\|ryP	MoD3V2FPT0WU
LS-513	NYLISJlZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTBwM{mwO\|Eh\|ryP	NFOzXIlUSU6JRWK=
NOMO-1	Mn;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4X2S2lEPTB;MD6zPVk4OSEQvF2=	MX;TRW5ITVJ?
MS-1	M2jw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn25TWM2OD1yLkSwNVc4KM7:TR?=	NUT0bllvW0GQR1XS
EKVX	NHTpTYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\RXVZKSzVyPUCuOFQ1PjFizszN	MlfjV2FPT0WU
SK-MEL-2	Ml7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTBwNE[0JO69VQ>?	M3jpfnNCVkeHUh?=
HCC1187	NGfHUIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLuTWM2OD1yLkS2O\|Y5KM7:TR?=	MVLTRW5ITVJ?
HCC2218	NWi2SXNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzWNZRKSzVyPUCuOFczOjdizszN	NIjNe3lUSU6JRWK=
NCI-H187	NHzSWnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{GxXmlEPTB;MD60O\|g1KM7:TR?=	M37sXXNCVkeHUh?=
DB	NH\IUHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTBwNUCwOVUh\|ryP	NH2zPI5USU6JRWK=
NCI-H69	NFjxUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXu4d4pYUUN3ME2wMlUxOjR5IN88US=>	MkX6V2FPT0WU
NCI-H1694	M1:wbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zVVGlEPTB;MD61NFY6PyEQvF2=	M2HGOnNCVkeHUh?=
CA46	NX3NVXdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDETWM2OD1yLkWwPVE4KM7:TR?=	NYTNTXYyW0GQR1XS
EHEB	M1G1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDsWI9KUUN3ME2wMlUyOTl\|IN88US=>	NXfuSlk3W0GQR1XS
NCCIT	NGq5e\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTBwNUSzNlEh\|ryP	NFXVSXNUSU6JRWK=
NCI-H720	M1;U[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTBwNUS5OlIh\|ryP	NI\yO4NUSU6JRWK=
LU-134-A	MlX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPwV4dKSzVyPUCuOVUzQTZizszN	MXrTRW5ITVJ?
MC-CAR	NXf4Z3FXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTBwNUW0N\|Eh\|ryP	M1ntbXNCVkeHUh?=
NEC8	Mk\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PCdGlEPTB;MD61OlE4OiEQvF2=	NFm4TYVUSU6JRWK=
NCI-H524	NUT3c3FJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXabop{UUN3ME2wMlU5PzR6IN88US=>	NV3TU\|RrW0GQR1XS
NCI-H1963	NFj2WJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHGxfZdKSzVyPUCuOlI2QCEQvF2=	MWLTRW5ITVJ?
SU-DHL-1	NUXhflZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PrR2lEPTB;MD62OFUzPiEQvF2=	MmrUV2FPT0WU
NCI-H1522	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfye2NKSzVyPUCuOlQ5QDNizszN	NWT5O\|dJW0GQR1XS
NCI-H1155	MnzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DsT2lEPTB;MD62OVM2KM7:TR?=	NXy1O4hIW0GQR1XS
D-263MG	NWjKWWdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPndWVKSzVyPUCuOlYyODFizszN	MXzTRW5ITVJ?
TE-6	NX3hW2FKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3Jd41KSzVyPUCuOlgyODRizszN	NYTs[ZFoW0GQR1XS
NCI-H1417	M{XS[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHpTWM2OD1yLk[5O\|EyKM7:TR?=	M3faOHNCVkeHUh?=
NCI-H510A	NFfhWpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk[4TWM2OD1yLke3NlM3KM7:TR?=	NXvOepB[W0GQR1XS
KARPAS-45	M1Lhdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;uNINKSzVyPUCuO\|gzOzVizszN	NYrIU4MyW0GQR1XS
IST-SL1	M3XNbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jSO2lEPTB;MD64OVgzPSEQvF2=	NVLTfXRRW0GQR1XS
COLO-824	NE[ySZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3Owb2lEPTB;MD64O\|g{PSEQvF2=	MkfpV2FPT0WU
NCI-H526	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2Dmb2lEPTB;MD65NFk2QCEQvF2=	MVXTRW5ITVJ?
NCI-H719	NUDQO2FUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHOOZJPUUN3ME2wMlk3PjV5IN88US=>	MV3TRW5ITVJ?
SF539	NHXFcYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDPfYpKUUN3ME2wMlk5Ozl4IN88US=>	M1i4eHNCVkeHUh?=
NKM-1	M1zlUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTBwOUi2OlMh\|ryP	NH;SPXdUSU6JRWK=
A253	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTvWIVpUUN3ME2wMlk5QDh3IN88US=>	M{D0SHNCVkeHUh?=
TE-441-T	NUjjXlBXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjCTnRRUUN3ME2xMlA1OzVizszN	NWH0T3RpW0GQR1XS
COR-L88	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTFwMUGzOVQh\|ryP	NXPVOXE{W0GQR1XS
CPC-N	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7abIpmUUN3ME2xMlE2QDh6IN88US=>	MVPTRW5ITVJ?
NCI-H2107	NXzDU5A{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPWVWdKSzVyPUGuNVczPjFizszN	MnfpV2FPT0WU
ECC4	NHW0[nlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTFwMUi2PVMh\|ryP	MnuyV2FPT0WU
NCI-H2141	M37ZUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TXOWlEPTB;MT6xPVI6QSEQvF2=	NGf1b3lUSU6JRWK=
NCI-H1770	MnrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fDWWlEPTB;MT6zNlkzQCEQvF2=	M3vVU3NCVkeHUh?=
NCI-SNU-1	NFnNdW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTMTWM2OD1zLkOzNFQh\|ryP	MlvNV2FPT0WU
LU-165	M3vRXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XUW2lEPTB;MT60OVQ3PyEQvF2=	MnrxV2FPT0WU
Raji	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LGfWlEPTB;MT60O\|I2QSEQvF2=	M{P4NXNCVkeHUh?=
EW-24	MmT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjqTG1UUUN3ME2xMlU1PjF7IN88US=>	NUjodFZFW0GQR1XS
KP-N-RT-BM-1	NWewUWFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mof2TWM2OD1zLkW2OVUyKM7:TR?=	MWHTRW5ITVJ?
SK-MEL-1	NWrHZZpzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTFwNkS4O\|ch\|ryP	NIHPb4hUSU6JRWK=
SCLC-21H	NEX1cYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3OeYxyUUN3ME2xMlY3PjVzIN88US=>	M3TkdnNCVkeHUh?=
SIMA	NGPGXWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETa[mxKSzVyPUGuOlgzOzNizszN	M2Dp[XNCVkeHUh?=
NCI-H1304	Mn73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTFwN{C3OlUh\|ryP	NX3q[4JbW0GQR1XS
REH	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7NTWM2OD1zLkexNFc5KM7:TR?=	M3r3SnNCVkeHUh?=
KP-N-YS	MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjU[VhsUUN3ME2xMlk{PTVzIN88US=>	NUnlR\|JWW0GQR1XS
DMS-153	M3jnOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\vVGlEPTB;MT65O\|U6KM7:TR?=	NWe2Um5mW0GQR1XS
NB10	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXf3RVd5UUN3ME2yMlIxQDd6IN88US=>	NIH2dHZUSU6JRWK=
NCI-H345	NV;ScnJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTJwNkG5NFUh\|ryP	NF7RVY5USU6JRWK=
SK-N-FI	NV3rNXRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTJwN{WzPFEh\|ryP	MlqxV2FPT0WU
NCI-H1092	M3;BbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTJwOUWzPVQh\|ryP	MkfxV2FPT0WU
KM-H2	M3PFV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnUTWM2OD1\|Lk[1N\|k3KM7:TR?=	M3frc3NCVkeHUh?=
KG-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIf3cIVKSzVyPUOuO\|E3QDhizszN	NW\tToxWW0GQR1XS
D-283MED	NHHISpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTNwN{W4O{DPxE1?	NFvQeYFUSU6JRWK=
LU-65	M1;nW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TaW2lEPTB;ND6xNVQ5PSEQvF2=	NYXGcWZpW0GQR1XS
MSTO-211H	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTRwMUi4PVgh\|ryP	MlXOV2FPT0WU
NCI-H2081	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWG0Zo85UUN3ME20MlI6OTd2IN88US=>	MkWzV2FPT0WU
D-247MG	M4XGfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDESnJNUUN3ME20MlQ{OTlzIN88US=>	NVr0bZBwW0GQR1XS
P31-FUJ	MknMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jOXWlEPTB;ND60OVAyQSEQvF2=	NWXFbYxpW0GQR1XS
DMS-79	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\vd\|JKSzVyPUSuPVMyQDNizszN	MlnxV2FPT0WU
KASUMI-1	NXWwfnNWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPUZmhkUUN3ME20Mlk4PTB7IN88US=>	MWLTRW5ITVJ?
JVM-3	NIfBUFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknyTWM2OD13LkK1NFE1KM7:TR?=	MnnDV2FPT0WU
LAN-6	M4LZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLjV\|BoUUN3ME21MlUyPzN4IN88US=>	M2XIcXNCVkeHUh?=
DJM-1	NF\LeFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\Ie2lEPTB;NT61OlAzQSEQvF2=	M{XYe3NCVkeHUh?=
JVM-2	Mn;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTVwNkewPVIh\|ryP	MVzTRW5ITVJ?
U-87-MG	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnxcFJSUUN3ME21Mlg6QTZ2IN88US=>	M13ZVXNCVkeHUh?=
SHP-77	NVHFWGFQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVuxN5J5UUN3ME21Mlk1QTJ6IN88US=>	NF7jRldUSU6JRWK=
RPMI-8866	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV[xcFZUUUN3ME22MlI4ODF\|IN88US=>	NIjEOmtUSU6JRWK=
ES7	NH2wS3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vqTmlEPTB;Nj6zPVkzPCEQvF2=	NFfXTVZUSU6JRWK=
WSU-NHL	MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTZwNUG2NFkh\|ryP	M1LacHNCVkeHUh?=
CAS-1	M4DmW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTdwMEm3OFkh\|ryP	NW\hdYxRW0GQR1XS
MHH-NB-11	M1nqWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\LNXZKSzVyPUiuNlMyPTJizszN	MU\TRW5ITVJ?
ES5	NYLtb3ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfH[2d[UUN3ME25MlUzOjh4IN88US=>	M1vGenNCVkeHUh?=
HDLM-2	MojzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\PTWM2OD17Lkm1PVAzKM7:TR?=	MVjTRW5ITVJ?
NCI-H2171	NFfXT4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jGUWlEPTB;MUCuOVkzPyEQvF2=	Mn\5V2FPT0WU
LNCaP-Clone-FGC	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jJWGlEPTB;MUGuN\|cyQCEQvF2=	NGrMNGxUSU6JRWK=
NCI-H1395	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\xUYs{UUN3ME2xNk4zPjl7IN88US=>	NHHRUlVUSU6JRWK=
NCI-H1436	NYK2WXl{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2jWWGlEPTB;MUOuN\|E6PSEQvF2=	M2n1T3NCVkeHUh?=
RCC10RGB	NGO0RZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPKfoVUUUN3ME2xN{4{OjJzIN88US=>	Mmn0V2FPT0WU
SW684	NUfv[4JRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NETqcmdKSzVyPUGzMlk4QTdizszN	NUTRfGE4W0GQR1XS
NCI-H1650	NHPkW5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYXEblh6UUN3ME2xOU4xPDR5IN88US=>	MV;TRW5ITVJ?
EW-13	MkjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7nOWRKSzVyPUG1MlIxOjFizszN	M1zpSHNCVkeHUh?=
EC-GI-10	NInjWY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTF3Lki2OFQh\|ryP	NFvNR5RUSU6JRWK=
CHP-126	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF6xXGlKSzVyPUG3MlE6OThizszN	MXHTRW5ITVJ?
NCI-H226	NFnJcI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH64T4RKSzVyPUG4MlA1ODNizszN	MYTTRW5ITVJ?
NCI-H1838	NHn2fmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\NRppVUUN3ME2yNE4yQDR6IN88US=>	NHnoSVJUSU6JRWK=
EW-11	M{\ZcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;4cmllUUN3ME2yOE4zPzF6IN88US=>	MYXTRW5ITVJ?
EB2	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTLVlVMUUN3ME2zNU42OzF6IN88US=>	Mm\aV2FPT0WU
D-502MG	Mn;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnP4TWM2OD12Mz65NlI6KM7:TR?=	MWHTRW5ITVJ?
U-698-M	NYOzSnlHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITKXmhKSzVyPUS4Mlg3PzFizszN	M37rUXNCVkeHUh?=
ES3	Ml;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTR7LkO4PVMh\|ryP	MUjTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo

Torin1 is efficacious at a dose of 20 mg/kg in a U87MG xenograft model and demonstrates good pharmacodynamic inhibition of downstream effectors of mTOR in tumor and peripheral tissues. ^[2]

Protocol

Kinase Assay:^[1]	+ Expand mTORC1 and mTORC2 in Vitro Kinase Assays: To produce soluble mTORC1, HEK-293T cell lines that stably express N-terminally FLAG-tagged Raptor are generated using vesicular stomatitis virus G-pseudotyped MSCV retrovirus. For mTORC2, similar HeLa cells that stably express N-terminally FLAG-tagged Protor-1 are generated. Both complexes are purified by lysing cells in 50 mm HEPES, pH 7.4, 10 mm sodium pyrophosphate, 10 mm sodium β-glycerophosphate, 100 mm NaCl, 2 mm EDTA, 0.3% CHAPS. Cells are lysed at 4 °C for 30 min, and the insoluble fraction is removed by microcentrifugation at 13,000 rpm for 10 min. Supernatants are incubated with FLAG-M2 monoclonal antibody-agarose for 1 h and then washed three times with lysis buffer and once with lysis buffer containing a final concentration of 0.5 M NaCl. Purified mTORC1 is eluted with 100 μg/mL 3×FLAG peptide in 50 mm HEPES, pH 7.4, 100 mm NaCl. Eluate can be aliquoted and stored at -80 °C. Substrates S6K1 and Akt1 are purified. Kinase assays are performed for 20 min at 30 °C in a final volume of 20 μL consisting of the kinase buffer (25 mm HEPES, pH 7.4, 50 mm KCl, 10 mm MgCl₂, 500 μm ATP) and 150 ng of inactive S6K1 or Akt1 as substrates. Reactions are stopped by the addition of 80 μL of sample buffer and boiled for 5 min. Samples are subsequently analyzed by SDS-PAGE and immunoblotting.
Cell Research:^[1]	+ Expand Cell lines: MEFs Concentrations: ~250 nM Incubation Time: 4 days Method: Cell viability is assessed with the CellTiter-Glo Luminescent Cell Viability Assay. On Day 0, 96-well plates are seeded with 500 cells per well and grown overnight. On Day 1, cells are treated with the appropriate compounds and subsequently analyzed on Days 3-5. For analysis, plates are incubated for 60 min at room temperature; 50 μL of CellTiter-Glo reagent is added to each well, and plates are mixed on an orbital shaker for 12 min. Luminescence is quantified on a standard plate luminometer. (Only for Reference)
Animal Research:^[2]	+ Expand Animal Models: U87MG xenograft model Formulation: Torin1 powder is first dissolved at 25 mg/mL in 100% N-methyl-2-pyrrolidone and subsequently diluted 1:4 with sterile 50% PEG400 to a final concentration of 5 mg/mL Dosages: 20 mg/kg Administration: Administered via i.p. once daily (Only for Reference)

References

[4] Dowling RJ, et al, Science, 2010, 328(5982), 1172-1176.

+ Expand

Solubility (25°C)

In vitro	DMSO	2 mg/mL (3.29 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 20% NMP+50% PEG 400 For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Torin 1 SDF

Molecular Weight	607.62
Formula	C₃₅H₂₈F₃N₅O₂
CAS No.	1222998-36-8
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to re-constitute the inhibitor for i.p. administration?
Answer:
S2827 Torin 1 can be dissolved in 5% DMSO/30% PEG 300/ddH2O at 0.25 mg/ml clearly, and in 10% DMSO/corn oil at 0.5 mg/ml, it is also a clear solution.

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Selective mTOR inhibitor

Rapamycin (Sirolimus) : mTORC1-selective, IC50=~0.1 nM.
Most Potent mTOR Inhibitor

Rapamycin (Sirolimus) : mTOR, IC50=~0.1 nM.
FDA-approved mTOR Inhibitor

Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).
Newest mTOR Inhibitor

XL388 ^New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

Related mTOR Products4

MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.
AZD8055

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

Features:First drug to inhibit both types of mTOR protein.
Temsirolimus (CCI-779, NSC 683864)

Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.
Sapanisertib (INK 128, MLN0128,TAK-228)

Sapanisertib (INK 128, MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.
Tacrolimus (FK506)

Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.
KU-0063794

KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Choose Your Country or Region

By Signaling Pathways

By product type

Torin 1